US Cardiology Review,
Journal Year:
2025,
Volume and Issue:
19
Published: April 28, 2025
Patients
with
atherosclerotic
cardiovascular
disease
(ASCVD),
such
as
those
a
history
of
MI
or
stroke,
are
at
high
risk
for
morbidity
and
mortality
associated
future
events.
Ideal
management
these
patients
requires
multifactorial
strategy
factor
mitigation
prevention
additional
Traditional
secondary
involves
lipid-lowering
statins,
blood
pressure
control,
anti-platelet
treatment.
Several
targets
have
been
identified
to
optimize
the
ASCVD,
further
lipid
inflammation
management,
lifestyle
weight
optimization,
strict
diabetes
use
β-blockers,
renin–angiotensin–aldosterone
system
inhibitors,
vaccinations,
considerations
anti-thrombotic
therapies.
This
review
will
describe
interventions
targets,
well
relevant
research
indications
European Heart Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 30, 2025
Graphical
AbstractThe
top
10
papers
in
dyslipidaemias:Left
hand
side
shows
the
lipid/lipopprotein
targets
and
right
what
are
new
developments
related
to
lipoprotein
as
discussed
text.Open
tabDownload
slide
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(3), P. 1026 - 1026
Published: Jan. 25, 2025
Pharmaceutical
advancements
and
an
improved
understanding
of
pathophysiology
have
enabled
innovative
therapies
for
chronic
conditions
like
dyslipidemia.
This
condition
is
marked
by
abnormalities
in
lipid
homeostasis.
Nucleic
acid
therapeutics,
including
antisense
oligonucleotides
small
interfering
RNAs,
are
novel
management
strategies
that
silence
genes
targeting
mRNA.
Antisense
modify
mRNA
to
inhibit
protein
production,
whereas
RNAs
induce
degradation
via
the
RNA-induced
silencing
complex
(RISC),
thus
offering
promising
treatments
dyslipidemia
atherosclerotic
cardiovascular
disease.
Chemical
modifications
improve
their
stability
targeting.
RNA-based
PCSK9,
Lp(a),
ApoC-III,
ANGPTL3
hold
transformative
potential
treating
effectively.
article
discusses
latest
data
from
completed
ongoing
trials
on
RNA
dyslipidemia,
inclisiran,
pelacarsen,
olpasiran,
zerlasiran,
lepodisiran,
volanesorsen,
olezarsen,
plozasiran,
zodasiran,
solbinsiran.
Each
therapy
targets
specific
molecules
while
also
significantly
impacting
other
parameters.
The
results
these
indicate
improvements
risk
reduction,
with
studies
expected
further
refine
role
agents
effective
management.
Current Opinion in Lipidology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 20, 2025
Purpose
of
review
The
study
naturally
occurring
genetic
variation
in
human
populations
has
laid
the
foundation
for
proprotein
converts
subtilisin/kexin
type
9
inhibitors,
and
more
recently
new
classes
lipid-lowering
drugs
such
as
lipoprotein(a)
inhibitors
lipoprotein
lipase
pathway
activators.
These
emerging
therapies
lower
plasma
lipoprotein-lipid
levels
that
are
not
adequately
managed
by
traditional
low-density
(LDL)
cholesterol-lowering
medications.
By
targeting
different
risk
factors,
these
could
help
manage
important
residual
cardiovascular
LDL
cholesterol
Recent
findings
We
latest
insights
into
pharmacological
modulation
therapeutic
targets.
highlight
remarkably
recapitulate
lipid
effects
observed
studies.
In
addition
to
lowering
levels,
robust
evidence
support
may
prevent
cardiometabolic
outcomes.
Summary
Emerging
launch
a
era
preventive
medicine
which
treatments
optimally
tailored
patient's
profiles.
Diabetes Obesity and Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 21, 2025
To
evaluate
the
efficacy
and
safety
of
siRNA
drugs
that
lower
Lp(a)
in
patients
with
dyslipidaemia.
A
network
meta-analysis
systematic
review
were
conducted
to
compare
targeting
Lp(a),
based
on
relevant
randomized
controlled
trials
(RCTs).
comprehensive
search
was
performed
PubMed,
Embase,
Web
Science
Cochrane
Library
(up
October
24,
2024).
RCTs
an
intervention
duration
at
least
12
weeks
included.
Eligible
studies
compared
reduce
including
both
Lp(a)-targeted
non-targeted
agents,
placebo
or
other
Lp(a).
The
primary
outcomes
percentage
reduction
absolute
low-density
lipoprotein
cholesterol
(LDL-C),
apolipoprotein
B
(apo(B)),
adverse
events
serious
events,
injection-site
reactions.
risk
bias
assessed
using
Risk
Bias
Tool
(ROB2),
a
random-effects
frequentist
approach.
Confidence
effect
estimates
evaluated
In
Network
Meta-Analysis
(CINeMA)
framework.
total
14
involving
5646
participants
particularly
Olpasiran,
demonstrated
strong
significantly
reducing
levels,
greatest
(mean
difference
[MD]:
-92.06%;
95%
CI:
-102.43%
-81.69%;
P-score:
0.98).
Olpasiran
also
showed
(MD:
-250.70
nmol/L;
confidence
interval
[CI]:
-279.89
-221.50;
0.99).
Certain
non-Lp(a)-targeted
such
as
inclisiran
zodasiran,
modest
reductions
by
approximately
15%.
agents
reduced
LDL-C
more
than
20%
decreased
apo(B)
terms
safety,
most
exhibited
favourable
profiles
no
significant
differences
placebo.
However,
zerlasiran
raised
concerns
regarding
reactions
when
have
shown
robust
effectiveness
substantially
reductions,
moderate
improvements
concentrations.
Non-Lp(a)-targeted
demonstrate
levels.
profile
is
generally
favourable,
but
may
increase
incidence
Current Opinion in Lipidology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 20, 2025
Purpose
of
review
Elevated
lipoprotein(a)
[Lp(a)]
is
a
genetically
determined
independent
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
Current
guidelines
recommend
universal
testing
Lp(a)
once
in
an
individual's
lifetime,
with
management
intensification
those
elevated
levels.
However,
there
paucity
real-world
data
about
how
patients
are
managed
and
their
associated
risk.
The
purpose
this
to
discuss
recent
progress
the
establishment
registries
Lp(a).
Recent
findings
Multiple
that
include
have
been
established
various
countries.
These
studies
will
provide
snapshot
global
burden
condition
current
patterns
treatment
patient
population.
Summary
common
but
underdiagnosed
ASCVD.
National
international
needed
expand
our
understanding
improve
condition.
